Rsv virus-like particles and methods of use thereof

Patent metadata

Field	Value
Publication number	US-2026000750-A1
Application number	US-202519262633-A
Country	US
Kind code	A1
Filing date	Jul 8, 2025
Priority date	Oct 29, 2018
Publication date	Jan 1, 2026
Grant date	—

Abstract

The present disclosure relates to virus-like particles and vaccine compositions for inducing immunity and preventing respiratory syncytial virus (RSV) infection.

First claim

1 . A virus like particle (VLP) comprising a respiratory syncytial virus (RSV) M protein and an RSV M2-1 protein.

2 . The VLP of claim 1 , wherein the VLP comprises one or more additional RSV proteins.

3 . The VLP of claim 1 , wherein the VLP comprises an RSV F protein.

4 . The VLP of claim 3 , wherein the RSV F protein is selected from a group consisting of a pre-fusion form of the RSV F protein, a post-fusion form of the RSV F protein, and a carbonyl terminal portion of the RSV F protein.

5 . The VLP of claim 3 , wherein the RSV F protein comprises a sequence selected from the group consisting of SEQ ID NO: 23, SEQ ID NO: 26, SEQ ID NO: 29, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, and SEQ ID NO: 37.

6 . The VLP of claim 3 , wherein the carbonyl terminal portion of the RSV F protein comprises a sequence of SEQ ID NO: 32.

7 . The VLP of claim 1 , wherein the VLP comprises an RSV G protein.

8 . The VLP of claim 7 , wherein the RSV G protein is from RSV group A or RSV group B.

9 . The VLP of claim 7 , wherein the RSV G protein comprises a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21.

10 . The VLP of claim 1 , wherein the VLP comprises a recombinant RSV G protein.

11 . The VLP of claim 10 , wherein the recombinant RSV G protein comprises a transmembrane domain of an RSV G protein and a central conserved domain of the RSV G protein.

12 . A vaccine comprising the VLP of claim 1 .

13 . The vaccine of claim 12 , further comprising an adjuvant.

14 . A method of inducing immunity to RSV infection or at least one symptom thereof in a subject, comprising administering one or more effective doses of the vaccine of claim 12 .

15 . The method of claim 14 , wherein the one or more effective doses of the vaccine are administered to the subject via a route that is selected from the group consisting of an intramuscular route, a subcutaneous route, an intradermal route, an oral administration, a nasal administration, and inhalation.

16 .- 27 . (canceled)

Assignees

• Univ Emory
• Children’S Healthcare Of Atlanta
• Wisconsin Alumni Res Found

Inventors

• Ha Binh
• Anderson Larry J
• Wright Elizabeth R

Classifications

• C12N2760/18034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/18023

  Virus like particles [VLP] · CPC title

• C12N7/00

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title

• C07K14/005

  from viruses · CPC title